Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: HFpEF and HFmrEF: what’s new in treatment? Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

ESC 365 is supported by

ESC 365 is supported by